Abstract |
The pharmacokinetics and toxicity of (-)-(S)- bromofosfamide ((2S)-(2-chloroethylamino)-3-(2-bromoethyl)-1,3,2-oxazaphosphorinae 2-oxide, CAS 146452-37-1, CBM-11) were determined in ten patients with non-small cell lung cancer following an oral dose of 1.38 g/m2 B.S.A. (Body Surface Area). The drug was given as a powder in gelatine capsules to fasting patients. Plasma samples were collected during the first 24 h after administration. All samples, after extraction with chloroform, were assayed by a reverse phase HPLC method using UV detection at 200 nm. Orally administered (-)-(S)- bromofosfamide showed relatively fast absorption kinetics. Peak concentration of 47 micrograms/ml was observed after 1 h. The average half-life was about 5 h. Toxicities associated with oral (-)-(S)- bromofosfamide therapy consisted of symptoms regarding the central nervous system, gastrointestinal tract and urinary tract. Neurotoxic symptoms were the most common clinically significant side effects and probably dose limiting.
|
Authors | K Kobylińska, P Koralewski, B Sobik, M Gasiorek, M Kobylińska |
Journal | Arzneimittel-Forschung
(Arzneimittelforschung)
Vol. 51
Issue 7
Pg. 600-3
( 2001)
ISSN: 0004-4172 [Print] Germany |
PMID | 11505793
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- bromofosfamide
- Ifosfamide
|
Topics |
- Administration, Oral
- Aged
- Antineoplastic Agents, Alkylating
(adverse effects, pharmacokinetics)
- Area Under Curve
- Blood Cell Count
- Bone Marrow Diseases
(chemically induced, pathology)
- Carcinoma, Non-Small-Cell Lung
(metabolism)
- Chromatography, High Pressure Liquid
- Female
- Half-Life
- Humans
- Ifosfamide
(adverse effects, analogs & derivatives, pharmacokinetics)
- Lung Neoplasms
(metabolism)
- Male
- Middle Aged
- Spectrophotometry, Ultraviolet
|